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Background: With the increasing utilization of 68Ge-68Ga radionuclide generators, 68Ga labelled peptides like
DOTATATE are receiving more attention in nuclear medicine. On the one hand, the long half-life of the parent
nuclide 68Ge is an enormous advantage for routine applications, but the question of the long-term stability of the
68Ge breakthrough arises, which up to now has scarcely been investigated.
Method: A sum of 123 eluates from four different 68Ge-68Ga generators (iThemba Labs, Faure, South Africa) and
115 samples of the prepared radiopharmaceutical 68Ga-DOTATATE were measured first with a dose calibrator and
again after decay of the eluted 68Ga via gamma-ray spectrometry. A complete decay curve was recorded for one
sample eluate. A further three eluates were eluted in ten fractions of 0.5 ml in order to obtain detailed information
concerning the distribution of the two nuclides within the eluates. The influences of factors such as the amount of
DOTATATE, addition of Fe3+ salts and replacement of HEPES buffer with sodium acetate on the radiochemical
synthesis were also tested.
Results: The content of long-lived 68Ge breakthrough increases over the entire period of use to more than
100 ppm. The labelling process with the chelator DOTA removes 68Ge efficiently. The maximum activity found in
the residues of the radiopharmaceuticals investigated in this study was below 10 Bq in nearly all cases. In many
cases (12% of the labelled substance), the long-lived parent nuclide could not be identified at all. The labelling
process is still viable for reduced amounts of the chelator and with acetate buffer.
Conclusion: Effective doses received by the patient from 68Ge in the injected radiopharmaceutical 68Ga-DOTATATE
are lower than 0.1 μSv and are therefore practically negligible, especially when compared with the contribution of
the PET radiopharmaceutical itself. Gamma-ray spectrometry as recommended by the European Pharmacopeia is
suitable for quantification of radionuclidic impurities.
Keywords: 68Ge-68Ga radionuclide generator; Radionuclide purity; Gamma-ray spectrometry; PET* Correspondence: Ferdinand.Sudbrock@uk-koeln.de
†Equal contributors
Department of Nuclear Medicine, University Hospital of Cologne, Kerpener
Str 62, Cologne NRW 50937, Germany
© 2014 Sudbrock et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited.
Sudbrock et al. EJNMMI Research 2014, 4:36 Page 2 of 10
http://www.ejnmmires.com/content/4/1/36Background
In recent years, the generator-produced 68Ga has attracted
increasing interest [1-8]. The ‘new trend’ [9] in nuclear
medicine is based on the 68Ge/68Ga generator that has
been discussed long [10-12]. Its short half-life makes 68Ga
excellently suitable for imaging in nuclear medicine.
Through trivalent 68Ga(III) cations bound to DOTA-
conjugated peptides, the radiopharmaceutical gains high
affinity to the somatostatin receptor SSTR2 [2,6,13,14].
68Ga undergoes disintegration via β+ decay and electron
capture with a half-life of 67.8 min and emits high
energy positrons of ca. 1.9 MeV (Table 1) [15].
The mother nuclide of 68Ga is the relatively long-lived
68Ge (T1/2 = 270 days) that nowadays is commonly pro-
duced by the nuclear reaction 69Ga(p,2n)68Ge on enriched
69Ga or on natural gallium as target material containing
the stable nuclide 69Ga with an abundance of 60% [6]. The
comparably long half-life of 68Ge gives 68Ga an enormous
advantage as a generator-based radionuclide. Due to high
reaction cross-sections in the energy range of 10 to
20 MeV [8], this reaction appeared suitable in spite of the
long half-life of the product nuclide which usually requires
a long irradiation. Details on the production, i.e. target
materials, yields of different nuclear reactions for gallium
targets and possible generators were studied in the early
1980s, e.g. [11,16]. Meanwhile, different generator types
have become commercially available, and the respective
generator concepts are discussed in detail by Rösch
[12]. The most common generators use matrices of
TiO2 or SnO2 from which Ga
3+ is eluted with HCl while
Ge4+ remains adsorbed. The generator used in this
study is based on SnO2, which, in comparison to TiO2,
requires a higher concentration of the eluant (0.6 M in-
stead of 0.1 M HCl) and, due to the lower pH, a differ-
ent labelling strategy. Further discussions have focused
on matrix-derived metallic impurities, which might
affect the labelling efficiency [17].
The problem of unnecessary patient exposure to radi-
ation could arise from two sources: 68Ge breakthrough
that is not removed in the labelling process and possibly
imperfect labelling, leading to an insufficient yield and,
hence, to free 68Ga in the radiopharmaceutical. As they
have an influence on the labelling process, traces of non-
radioactive metallic contaminants in the eluate have to
be taken into account. The requirements on the quality
of the primarily eluted gallium chloride solution as well
as the labelled compound are defined in the EuropeanTable 1 Nuclear data for 68Ga and 68Ge
Nuclide Half-life Gamma rays and abundance
Ga-68 67.629 min 805.75 keV (0.084), 1,077.35 keV (3.0), 1,260
1,883.09 keV (0.138)
Ge-68 270.8 days No gamma rays, determination via decay t
The abundance values are enclosed in parentheses. Asterisk denotes an endpoint ePharmacopeia (Ph Eur) [18,19]. The radionuclidic purity
of 68Ga in the gallium chloride solution is limited to a
minimum of 99.9% of the total radioactivity [18], but the
content of 68Ge should not exceed 0.001% [18]. Gamma-
ray spectrometry is recommended as the method of choice
for the determination and quantification of the impurities.
The European Pharmacopeia states precisely that peaks in
the gamma-ray spectra that do not belong either to 68Ga
(Table 1), to annihilation radiation or a possible sum peak
at 1,022 keV shall ‘represent not more than 0.1 per cent of
the total radioactivity’ [18].
In this study, we assessed the 68Ge breakthrough in
123 eluates of four SnO2-based
68Ge/68Ga generators
and the 68Ge content in 115 samples of the radiopharma-
ceutical after preparation of 68Ga-DOTATATE in order to
measure the depletion of 68Ge during a manual radio-
chemical synthesis. We studied the influence of different
amounts of DOTATATE on the labelling process, the
feasibility of different buffers (acetate instead of HEPES)
as well as the influence of interfering ions such as Fe3+.
Methods
Generators, elution procedure and radiochromatography
Studies were performed using four generators between
December 2010 and April 2013. All generators had a
nominal activity of 1,850 MBq and were supplied by
iThemba Labs (Faure, South Africa provided by IDB Hol-
land BV, Baarle-Nassau, The Netherlands) [4,20]. Accord-
ing to the manufacturer, the mother nuclide is produced
via the nuclear reaction 69Ga(p,2n)68Ge. Apart from the
68Ge breakthrough, minor metallic impurities (Zn, Fe, Sn,
Ti, Cu and Al) represent a problem that has to be taken
into account [20]. As a decay product of the long-lived
mother nuclide, the concentration 68Zn is likely to
increase over the entire period of use (see, e.g. [17,20]
for details).
The first three generators were used over a period of
9 months, while the fourth generator was in use between
February and October 2013. 68Ga is eluted from the
generator with 5 ml HCl (c = 0.6 M) [20].
Three samples of 68Ga eluates were measured repeatedly
over a period of up to 7 months in order to obtain detailed
decay curves. A dose calibrator (VDC405, Veenstra Instru-
ments, Joure, The Netherlands) was used for the deter-
mination of 68Ga activities directly after elution (first day),
and measurements of the activity were continued, after
complete decay of the primarily eluted 68Ga, by high-Charged particles, particle type and abundance
.97 keV (0.083), 821.7 keV*, β+ (1.2); 1,899.1 keV*, β+ (87.7); electron
capture (11.1)
o Ga-68 Electron capture (100)
nergy.
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purity germanium detector system (HPGe, Ortec, Oak
Ridge, TN, USA).
Radiochromatography was performed by a fractionated
elution of the generator for three illustrative samples. In
this case, the generator was eluted as usual with 5 ml HCl
(0.6 M), and the eluate was separated into ten fractions of
0.5 ml each. Each fraction was measured first using the
dose calibrator and again, after decay of the primarily
eluted 68Ga, using gamma-ray spectrometry.
Standard manual radiochemical preparation of
68Ga-DOTATATE
A 500 mg (±3 mg) HEPES (Sigma-Aldrich Chemie
GmbH, Taufkirchen, Germany) was transferred into a ster-
ile 10-ml glass vial. A 50 μg DOTATATE (JPT, Berlin,
Germany) was dissolved in 100 μl Ultrapur® water (Merck
Millipore, Darmstadt, Germany) and added to the dry
HEPES powder. The 68Ge/68Ga-generator was eluted with
5 ml of 0.6 M HCl (made from 30% HCl, and water, both
Ultrapur® grade, Merck Millipore). Two milliliters of the
68Ga containing eluate was transferred to the HEPES/
DOTATATE mixture. After very careful shaking, the
mixture was heated for 15 min at 85°C in a heating
block. It was then removed from the heating block and
cooled down for 10 min before being diluted with 6 ml
water (Ultrapur®). The labelling mixture was purified on
a SepPak light C18 cartridge (Waters, Eschborn,
Germany) with 10 ml water (Ultrapur®) and eluted with
2 ml ethanol (70%, made from ethanol, ROTIPURAN®,
ROTH, Karlsruhe, Germany, and Ultrapur® water). The
cartridge was pre-conditioned by rinsing first with 5 ml
ethanol (70%), then with 10 ml Ultrapur® water and
5 ml air. Four milliliters of sterile isotonic saline (BERLIN-
CHEMIE AG, Berlin, Germany) was added to the ethano-
lic solution for injection. The preparations were followed
by a sterile filtration, and before administration, the prod-
uct is diluted with approximately 20 ml saline.
The radiochemical yield of the manual syntheses was
expressed as percentage of the activity used for the prep-
aration of 68Ga-DOTATATE and the activity in the final
product. The time for the whole process was exactly re-
corded (typically 30 min), and therefore, the radioactive
decay in the meantime could be corrected for.
The robustness of the manual radiochemical preparation
tested under different conditions
The robustness of the labelling process was tested to
establish three points:
(a) What is the critical amount of DOTATATE?
(b) Can HEPES be replaced by acetate as buffer?
(c) What is the critical concentration of iron as
ubiquitous metallic impurity?Different amounts of DOTATATE and acetate buffer
In order to analyse parameters that may influence the
abovementioned standard preparation technique, the syn-
thesis was carried out with three modifications for test
purposes. Thirteen preparations were performed with dif-
ferent amounts of DOTATATE (1, 3, 7, 10 and 15 μg) and
three further preparations with sodium acetate (130 and
164 mg) instead of HEPES buffer.
Addition of Fe3+
A further eight preparations were carried out after the
addition of Fe(NO3)3 · 9 H2O (Sigma-Aldrich) with dif-
ferent volumes and concentrations to obtain different
molar amounts of the trivalent cation. Fe(NO3)3 · 9 H2O
was added in the following concentrations and volumes:
1 mmol/l (100 and 10 μl), 500 μmol/l (10 μl), 100 μmol/l
(10 μl), 50 μmol/l (10 μl), 5 μmol/l (10 μl) and 1 μmol/l
(100 and 10 μl twice). Amounts of between 10−11 and
10−7 moles of Fe(NO3)3 · 9H2O were thereby obtained.
The radiochemical yields of the syntheses were assessed
for all tests. The radiochemical yield was expressed as the
fraction of the activity measured in the radiopharmaceuti-
cal in relation to the activity of 68Ga added to DOTATATE
after decay correction for the elapsed time. Radiochemical
purity was routinely assessed via thin-layer chromatog-
raphy (TLC, ITLC-SG, citrate buffer 0.1 M).
Samples, dose calibrator, gamma-ray spectrometry and
nuclear data
68Ga was measured with a dose calibrator VDC-405 in
the eluates immediately after elution and in the radiophar-
maceutical immediately after preparation. The activities of
68Ge in aliquots of eluates and radiopharmaceuticals were
determined after complete decay of 68Ga (t > 1 day) via
gamma-ray spectrometry using an electrically cooled
‘poptop’ coaxial HPGe detector with a crystal diameter
and length of 64.9 and 54.6 mm, respectively. The de-
tector has a high energy resolution of 0.95 keV @
122 keV 57Co and 1.9 keV @ 1,332 keV 60Co. The count-
ing efficiency for two positions over the whole energy
range from 50 to 2,000 keV was determined using cali-
brated standard samples (Figure 1). Spectral analyses
were performed by use of the programme Gamma-W
(Dr. Westmeier GmbH, Ebsdorfergrund-Mölln, Germany).
Over the study period, a total of 218 manual radio-
chemical and a further 13 test preparations of 68Ga-
DOTATATE were performed. The content of 68Ge was
determined in 123 eluates and 115 different 68Ga-
DOTATATE samples.
68Ge was determined in the eluates and the 68Ga-
DOTATATE residues using the 1,077-keV gamma-ray
emission of the daughter nuclide 68Ga, assuming that 68Ga
is replenished through decay of a possible breakthrough of












Geometry 1: Marinelli Beaker
Geometry 2: Distance Holder
Figure 1 Efficiency of the high-purity germanium detector.
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A total of 38 preparations over a period of 6 months
were monitored by means of a finger ring dosimeter
(position: middle finger, right hand) that was worn and
evaluated monthly by the North Rhine-Westphalian
Measurement Office in Dortmund (Materialprüfungsamt
Dortmund) in accordance with German legislation. The
number of preparations was recorded for every month.
The dose quantity recorded for measurements of the
hand was the personal dose equivalent Hp(0.07).Results and discussion
Results
Radiochromatography
Radiochromatography was performed on three eluates in
which a total of 1,221, 1,255 and 1,407 MBq 68Ga was
eluted in ten fractions of 0.5 ml. Between 1,100 and
1,300 MBq 68Ga (93% to 95%) were obtained in fractions 3




















Ga-68 (1) Dose Calibrator 
Ge-68 (1) HPGe
Ga-68 (2) Dose Calibrator
Ge-68 (2) HPGe 
Ga-68 (3) Dose Calibrator
Ge-68 (3) HPGe
Figure 2 Three elution profiles for 68Ga (large symbols) and
68Ge (small symbols).contain more than 70% of the total eluted activity. These
two fractions represent a very high activity concentration.
The sum of the 68Ge breakthrough in these ten fractions
yielded between 1.4 and 4.1 kBq. Hence, the fraction of
long-lived 68Ge in the 68Ga eluate corresponded to 1.2
to 3.3 ppm (0.00012% to 0.00033% or 1.2 to 3.3 Bq
(68Ge)/1 MBq (68Ga)).
Gamma-ray spectrometry, decay curves and radionuclide
impurities
All eluates were measured immediately after elution using
the dose calibrator and later on by means of gamma-ray
spectrometry. A complete decay curve of one illustrative
eluate is displayed in Figure 3. One day after elution, the
activity in the eluate is ten times higher than would be
expected from the calculated decay curve which is caused
by a breakthrough of 68Ge. Accordingly, the complex
decay curve exhibits two different Half-lifes: for the first
day after elution, a half-life of 67.93 min is found (dose
calibrator), while from day 2 to day 200, the calculated
half-life is 283 days (HPGe). The physical half-lives are
well reproduced for 68Ga and acceptably well for 68Ge
(Figure 3).
In the gamma-ray spectra of all eluates, peaks attribut-
able to 68Ga could be clearly identified a few days after
elution. The branching ratios of the gamma-ray emissions
of 68Ga are small (<5%, Table 1), but peaks belonging to
the four most abundant transitions were all found within
the spectra and none of them was obscured by any peak
from other nuclides, which would lead to an alteration of
the full-width at half maximum (FWHM) of the respective
photopeak. After a decay time of 2 days, further observ-
able peaks could be assigned to nuclides from the natural
decay chains or 40 K, the latter nuclide with a peak around
channel no. 2900 (Figures 4 and 5).
Figure 3 Decay curve for one eluate measured over 2 days. Inset: complete decay curve over 200 days.
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activities in the range between 10 and 30 MBq 68Ga was
in nearly all cases below 10 Bq of 68Ge. For a measuring
time of 1 to 3 days, the peak areas yielded hundred
counts or even fewer, and in some cases (N = 14), the
peak region around 1,077 keV was completely indistin-
guishable from the background. Yet, a few samples mea-
sured over more than 8 days undoubtedly gave a peak at
1,077 keV, albeit a ‘weak’ or ill-pronounced peak after 2
or 3 days. It was thus not practicable to measure many
more than 100 reserve samples for 8 days or longer. Due
to fluctuation of the background, it was also not feasible
to record and subtract a constant background activity
for each sample so that the activities of the given impur-
ities in 68Ga-DOTATATE preparations strictly represent
an upper limit for the content of long-lived impurities.
For the 1,077 keV photopeaks in the spectra, the back-
ground subtraction routine of the programme Gamma-W
was applied.
A typical gamma-ray spectrum of a residue of 68Ga-
















Figure 4 Gamma-ray spectrum of 68Ga-DOTATATE.the region around 1,077 keV is shown in Figure 5. The
peak at 1,120 keV (naturally occurring radionuclide from
the decay chain 4n + 2) can be seen more clearly. In 68Ga-
DOTATATE samples, the fraction of 68Ge in the radio-
pharmaceutical is, on average, below 1 ppm (<0.0001%,
mean 0.7 ppm, median 0.3 ppm). No further peaks could
be observed (Figures 4 and 5), and hence, gamma-
spectrometry proves that in all samples, only 68Ge has
to be considered as radionuclidic impurity.
Typically less than 10 Bq of 68Ge was detected in each
single residue of 68Ga-DOTATATE (N = 101 of 115) via
gamma-ray spectrometry [21]. In many residues, the
long-lived mother nuclide could not be identified at all
(N = 14 of 115). Sample descriptions, i.e. activities of the
residues of the eluates and DOTATATE are summarized
in Table 2.
The breakthrough in the eluates increases significantly
over the shelf-life of the generator as shown in the ex-



















E = 1120 keV
Ge-68 / Ga-68
E = 1077 keV
Figure 5 Gamma-ray spectrum of 68Ga-DOTATATE. Detailed
view of the region around channel no. 2200 (1,000 to 1,200 keV).
Table 2 Statistical distribution of activities in the 68Ga
eluates and in 68Ga-DOTATATE
Sample Activities (Ga-68) Activities (Ge-68)
Eluate (N = 123) Max 1,500 MBq 776 kBq
Min 41.5 MBq 0.1 kBq
Mean 474 MBq 50 kBq
Median 376 MBq 27 kBq
DOTATATE (N = 115) Max 68.2 MBq 11.4 Bq
Min 0.42 MBq 0 Bq*
Mean 21.1 MBq 4.6 Bq
Median 20.7 MBq 4.3 Bq
Asterisk means not detectable.
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but then increase. After a few months, the breakthrough
is usually in the region of 100 to 300 ppm (0.01% to
0.03%) with three single outliers beyond 500 ppm
(0.05%). The breakthrough of 68Ge shows a maximum of
800 ppm (0.08%) (Figure 6). The long-term constancy
for generator no. 2 was comparable to that for generator
no. 3, and the first 25 elutions of generator no. 4 show
similar results. Taking into account that 68Ge is presum-
ably the only radionuclidic impurity, the requirement of
the European Pharmacopeia for 68Ga (99.9%) is therefore
ensured.The robustness of the radiochemical preparation tested
under different conditions
The radiochemical purity of the purified injected prod-
uct was, in all cases, 99% (TLC). The radiochemical yield
(activity in the labelled product in relation to the initial
activity of 68Ga) ranges from 60% to 90% (Figure 7).
Figure 7 shows the yield of 20 routine preparations car-
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Figure 6 Long-term control of the 68Ge breakthrough in two
generators (□ = generator 2, ◊ = generator 3).Different amounts of DOTATATE and acetate buffer for
manual labelling After the addition of 1 μg DOTATATE,
the radiochemical yield of the preparation was 11% and
41%, while 3 μg DOTATATE yielded 15% and 16%, and
7 μg DOTATATE yielded 27% and 41%. Four preparations
with 10 μg DOTATATE yielded between 64% and 72%,
whereas the yield after addition of 15 μg DOTATATE fell
back to 43% (Figure 7). The radiochemical yield for a total
of 20 routine preparations was found to lie between 60%
and 90% (mean and median 75%). These 20 standard
manual procedures were performed at the same time as
the radiochemical test.
The content of 68Ge in the radiopharmaceutical ranged
from a non-detectable breakthrough (two samples) to
34 Bq of 68Ge after addition of 3 μg DOTATATE. The
values for 1 and 3 μg DOTATATE were slightly higher (11
to 34 Bq) than those for higher amounts of DOTATATE
(7 to 19 Bq). The radiochemical yield with sodium acetate
as buffer was found to lie between 74% and 82% (N = 3).
Addition of Fe3+ For different concentration of Fe3+
cations, the yield was also 74% (mean value) in most
cases (7 out of 9 preparations) (Figure 8). But after
addition of higher amounts of the trivalent cation (10 or
100 μl of a solution with a molar concentration of 1 mM),
the radiochemical yield decreased to 10% (Figure 8), and
the activity of 68Ga-DOTATATE became too low, i.e. in
the region of only 10 to 30 MBq. The 68Ge activity in the
labelled 68Ga radiopharmaceutical remained in all cases
below 5 Bq.
Extremity dosimetry of the personnel
The monthly assessed personal dose equivalent Hp(0.07)
was found to lie between 0 mSv (one preparation per
month in the recording period) and 5 mSv (ten prepara-
tions per month in the recording period). The average
dose, i.e. the monthly personal dose divided by the num-
ber of preparations, varied between 0 and 0.7 mSv, while
the average dose over the whole study period yielded
0.5 mSv for each synthesis.
Discussion
Radiochromatography
When a fractionated elution is carried out, almost the
complete amount of 68Ga is collected in four fractions
(nos. 3 to 6) or within 1.5 to 3 ml hydrochloric acid
(0.6 M), respectively. This is in good agreement with
previous reports from authors who used the most com-
mon TiO2-based generator [15,17,22-25] and in agree-
ment with a few authors who used a SnO2-based
generator from iThemba Labs, too [20]. The elution pro-
file presented in this work is comparable to TiO2-based
generators, although these two generators are eluted
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Figure 7 Radiochemical yield (68Ga-DOTATATE) for syntheses with different amounts of DOTATATE (filled diamonds). Yield of 20 routine
preparations (empty diamonds).
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scribed very early on by Pao et al. [16] for an elution via
hydrous zirconium oxide.
Gamma-ray spectrometry, decay curves and radionuclide
impurities
The breakthrough is specified by the manufacturers of
the 68Ge/68Ga generator as 0.0035% or 35 ppm, which
would be equivalent to 64.75 kBq in 1,850 MBq eluate.
For the first elutions after delivery of the generator, the
breakthrough does not in fact exceed this limit. But
strictly speaking, the limit of 0.001% suggested by the
European Pharmacopeia [18] is slightly exceeded in several
eluates from the three generators evaluated in this study.
The half-life found for the decay of the eluate on the first
day after elution (dose calibrator) reproduces the reported
half-life of 68Ga very well, while later, the decay of the long-
lived component follows with the half-life of 68Ge. This is a


























Figure 8 Radiochemical yield (68Ga-DOTATATE) after addition of diffeproven in detail for longer-lived nuclides via gamma-ray
spectrometry carried out after decay of the primarily
eluted 68Ga. Hence, as further radionuclidic impurities
can largely be excluded, the requirements of the Euro-
pean Pharmacopeia concerning the radionuclide purity
for 68Ga of 99.9% is most probably fulfilled [18,19].
The reason for the variable but increasing break-
through over time is not yet clear, but it does not appear
to depend on the time between the two elutions. The
time-dependent increase of the breakthrough resembles
that found by Asti et al. [17], Lin et al. [24] and Loktio-
nova et al. [26] for a different type of generator. For the
generator used in this study, the breakthrough exceeds
100 ppm (10−2%) after a shelf life of 100 days, whereas
the values presented by Lin et al. display a lower break-
through, especially for one of the TiO2-based generators
investigated by those authors [24].
In relation to the breakthrough of 68Ge in the eluate,
the final product is depleted by more than a factor of1,0E-09 1,0E-08 1,0E-07
f Fe3+ (Mol)
rent molar amounts of Fe3+.
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for the syntheses of 68Ga-DOTANOC [2], the prepar-
ation of 68Ga-DOTATATE as described in this study
removes 68Ge relatively efficiently. Other authors cited
by Belosi et al. [2] report an upper limit of 25 Bq 68Ge in
68Ga-DOTANOC. This is in good agreement with our
findings (Table 2). The significant reduction of the 68Ge
(IV) cations is presumably based on the fact that the
complexation of cations with DOTA is most effective for
trivalent metals [20,27].
As previously mentioned by Loc’h et al. [11], it is diffi-
cult to detect traces of further nuclides in the eluate due
to the high-energy emissions (Table 1) producing a high
Compton background. Methods to reduce the Compton
continua such as dedicated anti-Compton spectrometers
would be needed to circumvent this problem [28]. But the
presence of further nuclides in the radiopharmaceutical
can be largely excluded with one principal exception:
nuclides that do not emit gamma rays (pure β-emitters,
EC, etc.), which cannot be detected by this method but
might be present in the eluate and the radiopharmaceu-
tical. But it was clearly confirmed for 68Ge that the
preparation reduces Ge cations efficiently. Thin-layer
chromatography is suitable for the detection of the ma-
jority radiochemical impurities, but it has been argued
that some impurities formed by radiolysis may only be
detected by HPLC [29].
The robustness of the radiochemical preparation tested
under different conditions
Even the tiniest addition of 1 μg DOTATATE used in our
tests represents an excess of the chelator (1 μg ~ 7 × 10−10
moles) in comparison to the amount of 68Ga (150 MBq ~
10−10 g ~ 1.5 × 10−12 moles) and should therefore be suffi-
cient for the preparation. The labelling efficiency should
therefore be similar to higher DOTATATE amounts.
However, this is obviously not the case and might be ex-
plained by the influence of metallic impurities. Never-
theless, the addition of only 1 to 7 μg DOTATATE is
sufficient for removing the Germanium breakthrough.
For an addition of 10 μg or more, the yield of the
labelling process was between 65% and 68%. The syn-
thesis obviously remains robust down to this amount
of DOTATATE and delivers a product sufficient for
imaging even with an ‘aged’ generator.
Sodium acetate, an easily available and pharmacologic-
ally harmless buffer, is obviously able to replace HEPES.
HEPES is a Good buffer for maintaining physiological
conditions in cell cultures but poses some problems like
long-term stability especially when exposed to humid air
and light. Acetate as buffer represents further advantages
to HEPES as it is more easily available and cheaper.
For DOTATATE amounts of 50 μg (3.5 × 10−8 moles),
the addition of iron becomes critical in the presence ofmore than 10−8 moles of Fe3+. Any traces of iron as con-
taminant in solutions used for the radiochemical synthesis
will easily exceed this limit and will hence impede the
preparation of 68Ga-DOTATATE. One may draw the con-
clusion from the two ‘titration curves’ (Figures 7 and 8)
that the metallic impurities are in the region of 7 × 10−9
to 7 × 10−8. Though the manual preparation is obviously
robust, it remains questionable if manual syntheses
do perfectly agree with today’s requirements of good
manufacturing practice.
Dosimetric implications
Patients The manual preparation of 68Ga-DOTATATE
reduces the 68Ge content to less than 1 ppm, i.e. the ap-
plication of 200 MBq 68Ga-DOTATATE to the patient
leads to an unwanted incorporation of long-lived 68Ge in
the region of 200 Bq or even less [2,30]. A background
subtraction would lead to an even further reduction of
the calculated content of 68Ge in 68Ga-DOTATATE. Our
finding of an almost negligible and barely detectable
amount of 68Ge amount in 68Ga-DOTATATE compo-
nents is therefore not inconsistent with authors who
state that they did not find any 68Ge. Given an incorpo-
rated activity of 200 Bq 68Ge per application of 200 MBq
68Ga-DOTATATE, a minor total effective dose of 0.1 μSv
[31] is certainly not exceeded. This dosimetric estimation
supports the assessment of Breeman et al. [30].
Personnel The extremity dose is an important quantity
for the exposure of staff that has to be assessed regularly,
especially for a manual preparation with high-energy beta
emitters. Dosimetry by means of a finger ring dosimeter
demonstrated that annual dose limits will not be exceeded.
The data presented in this work represent an upper limit
(0.5 mSv/synthesis) because other handlings of radioactiv-
ity apart from preparations with 68Ga are recorded as well.
A high number of 200 preparations performed by one per-
son will yield 100 mSv, and even when taking the position
of the ring into account, which does not necessarily repre-
sent the highest extremity exposure, the annual limit of
500 mSv is unlikely to be reached.
Conclusions
Manual labelling
68Ga-DOTATATE can be prepared manually and safely
by the method described in this study without using any
dedicated automatic apparatus for synthesis. The synthesis
is robust as it will not fail when using more than 10 μg of
the chelator (2 ml eluate).
Metallic impurities
Interfering trivalent ions like Fe3+ (>10−8 moles, i.e.
2 nmol/ml) need to be excluded. In this study, it was
shown that the concentration of the interfering ions
Sudbrock et al. EJNMMI Research 2014, 4:36 Page 9 of 10
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1.4 nmol/ml.
Elution profile
If a high concentration of 68Ga in the eluate is required,
it appears recommendable to discard the first 1.5 ml and
to collect the following 1.5 ml for the radiochemical
labelling.
Breakthrough and radionuclidic purity
A small breakthrough of 68Ge into 68Ga is inevitable.
The radionuclidic purity of 68Ga in the eluate meets the
requirements of the European Pharmacopeia where a
minimum of 99.9% 68Ga in gallium chloride solutions is
specified. The 68Ge content exceeds the specification of
0.001% in some eluates, but in the labelled compound, it
certainly does not exceed this limit.
Gamma-ray spectrometry
Gamma-ray spectrometry as e.g. recommended by the
Monograph of the European Pharmacopeia is suitable
for the quantification of radionuclidic impurities in both
the eluate and the labelled substance. As no other nu-
clides are present in the samples, scintillation counting
would be sufficient, though high-resolution spectrometry
using high-purity germanium detectors is superior.
Dose estimation for the patient
The doses received by the patient from the long-lived
breakthrough are in the region of 0.1 μSv.
Radiation exposure of staff members
The manual labelling can be carried out without any
critical extremity exposures.
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